The rapid expansion of clinical trials in China has drawn attention, particularly in light of alarming reports regarding patient safety. While the country has become renowned for its swift and cost-effective clinical research, recent incidents have raised critical questions about the integrity of these trials.
In the summer, three fatalities emerged from clinical trials in China, including the tragic loss of two children. Alarmingly, these deaths were not disclosed to the public at the time they occurred.
Legislative Concerns
U.S. lawmakers, particularly Rep. John Moolenaar and Rep. Ben Cline, expressed their apprehensions in a letter addressed to FDA Acting Commissioner Kyle Diamantas. They detailed their concerns regarding the lack of transparency surrounding these incidents. “In one case, the sponsoring company halted all public updates about the treatment for over a year, only acknowledging the death after persistent inquiries,” they noted. They highlighted a troubling pattern: one child’s death was concealed while researchers continued to publish findings, and in another case, a patient’s death went unreported until months later, despite the FDA clearing the therapy for trials in the U.S.
The company associated with the latter incident, RiboX, claimed that the FDA had been informed of the death, which was included in their Investigational New Drug (IND) application.
Investigator-Initiated Trials (IITs)
All three fatalities occurred during investigator-initiated trials (IITs), which operate outside China’s typical IND framework. The first death was reported in August 2025, involving a boy with Duchenne muscular dystrophy participating in a CRISPR gene-editing trial at HuidaGene. The second involved a young girl undergoing a gene-editing procedure for a genetic neurodevelopmental disorder at Xinhua Hospital. The third patient was a man in his 50s suffering from systemic sclerosis and had significant pre-existing health issues, treated with RiboX’s experimental CAR-T cell therapy.
In light of these incidents, China has initiated measures to strengthen regulatory oversight around IITs through Order 818, which became effective on May 1.
Regulatory Changes
Prior to Order 818, the environment surrounding IITs in China resembled a “Wild West,” as described by Boyang Wang, founder of the global longevity fund Immortal Dragons. This order introduced a formalized commercial pathway for specific treatments, including gene editing and personalized cell therapies, outside the conventional drug approval process. It mandates partnerships with Level 3 Grade A hospitals and prohibits companies from charging patients for experimental treatments until a preliminary efficacy and safety benchmark, known as “translational approval,” is met. Foreign entities face existing investment restrictions, complicating their access to this new pathway.
Rapid Growth of Clinical Trials
China has experienced a meteoric rise in clinical trial volume, surpassing the United States in annual trial registrations by 2020 and reaching over 5,000 registered trials annually by 2024. However, concerns about transparency in addressing potential safety issues persist. Moolenaar and Cline emphasized the need for the FDA to play a more proactive role in scrutinizing data from Chinese trials that could influence U.S. drug approvals.
“China now conducts thousands of clinical trials each year, yet the American public has almost no insight into the operational aspects of these trials, the data collection processes, or whether adverse events are completely disclosed,” they stated.
Call for FDA Action
The lawmakers urged the FDA to reject data from China for investigational new drug applications, new drug applications, or biologics license applications unless an in-person audit of the trial site had occurred within the past year. They also requested a comprehensive evaluation of U.S. drug development and marketing approvals dependent on Chinese IITs and Clinical Trial Applications, especially concerning high-risk areas like gene editing.
The FDA acknowledged receipt of the letter and is currently reviewing it, according to a communication from the HHS Public Affairs office.
Accelerating U.S. Trials
Amid these developments, U.S. officials are working to expedite domestic clinical trials to maintain competitiveness with China, which can move drugs from initial research phases to investigational new drug applications 50% to 70% faster than other countries.
Operation TrialBlazer, launched earlier this year, includes initiatives aimed at shortening IND timelines and facilitating quicker transitions to human trials. The HHS has also indicated steps to clarify Phase 1 expectations and make late-stage trial designs more flexible.
Conclusion
As China continues to advance its clinical trial landscape, the urgency for enhanced transparency and safety protocols becomes increasingly apparent. The recent fatalities underscore the need for stringent oversight, not only for the protection of participants but also to maintain the integrity of global clinical research. The balance between innovation and patient safety remains a critical conversation as the biotech industry evolves.
- Increased scrutiny is necessary for clinical trials in China.
- Legislative action is prompting a review of data from Chinese trials.
- Transparency and safety protocols are vital for participant protection.
- The U.S. is working to enhance its clinical trial processes.
- A focus on regulatory oversight may improve the integrity of global research.
Read more → www.yahoo.com